64 Search Results


Search Again

Jan Abkowitz , MD

Email: janabk@u.washington.edu

Phone: (206) 685-7877

Dr. Abkowitz' work is focused on research in hematopoietic stem cells, erythropoiesis, heme physiology, marrow failure, myelodysplasia (MDS) and the clonal evolution of leukemia.

View Bio

Fred Appelbaum , MD

Email: fappelba@fredhutch.org

Phone: 206-667-4412

Dr. Appelbaum’s research focuses on the biology and treatment of leukemias, lymphomas and other blood cancers. He was the lead author of the first paper to describe the successful use of autologous bone marrow transplantation, a therapy now used in more than 30,000 patients annually. He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first monoclonal antibody approved by the Food and Drug Administration to treat acute myeloid leukemia.

View Bio

Alice Berger , PhD

Email: ahberger@fredhutch.org

Phone: (206) 667-6281

The goal of the Berger laboratory is to enable precision medicine by systematically uncovering the molecular alterations in cancer, determining the function of these variant alleles, and understanding how these alleles modulate response to targeted or immune-based therapies. Although many of the genes involved in cancer have now been identified, a major challenge is discovering which specific alleles of these genes are involved and how these alleles modulate therapeutic response. We combine functional genomics, computational biology, biochemistry, and genetics to understand the mechanism of somatic cancer variants. Our goal is to identify drug targets and biomarkers and to translate this knowledge into clinical benefit for patients.

View Bio

Irwin Bernstein , MD

Email: ibernste@fredhutch.org

Phone: (206) 667-1212

The research in Dr. Bernstein's lab has primarily focused on developmental aspects of hematopoiesis with the specific goal of developing novel therapeutic modalities.

View Bio

Marie Bleakley , MD

Email: mbleakle@fredhutch.org

Phone: (206) 667-6572

Dr. Bleakley's research is focused on improving outcomes for patients with high-risk leukemia by developing new strategies that optimize the activities of T cells in the context of HCT. In particular, she is working to promote the advantageous Graft-Versus-Leukemia (GVL) effect and reduce the potentially dangerous GVHD that also can be caused by donor T cells after allogeneic transplantation.

View Bio

Hamid Bolouri , PhD

Email: hbolouri@fredhutch.org

Phone: (206) 667-2748

Dr. Bolouri is interested in understanding how gene regulatory interactions control cellular state and identity, both in normal development and in diseases such as cancer. A particular focus of his lab is the development and use of integrative computational systems biology methods to map gene regulatory networks from whole genome data: currently they are working on identification of cis-regulatory sequence variations in childhood Acute Myeloid Leukemia.

View Bio

Ivana Bozic , PhD

Email: ibozic@uw.edu

Phone: (206) 543-5077

Dr. Bozic studies the evolution of cancer and its resistance to treatment through mathematical and computational modeling. Her interests lie in both theoretical aspects of these models and their application. On the theoretical side, Bozic studies stochastic processes, especially multi-type branching processes, and their finite time characteristics. Dr. Bozic collaborates extensively with experimental and clinical researchers to integrate modeling with clinical data, providing insight into the natural history of cancer in vivo.

View Bio

Ryan Cassaday , MD

Email: cassaday@uw.edu

Phone: (206) 288-1202

Dr. Cassaday is interested in testing novel treatments and developing improved risk-stratification methods for adults with acute lymphoblastic leukemia. In addition, he is studying radioimmunotherapy-based conditioning regimens for stem cell transplantation as treatment for adults with high-risk lymphoma.

View Bio

Aude Chapuis , MD

Email: achapuis@fredhutch.org

Phone: (206) 667-4369

Dr. Chapuis’ translational research laboratory is developing novel ways to modulate the immune system to target cancer. Her research is especially focused on 1) understanding the factors associated with successful “adoptive” transfer of immune T cells and improving the therapeutic efficacy of both natural (native) and gene-modified T cells targeting viral and tumor antigens, and 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T cells so as to better eliminate tumor targets. These advances are in turn used to 3) develop clinical strategies to optimally activate therapeutic T cells to specifically eliminate cancer in patients, without the noxious side effects of chemotherapy.

View Bio

Thomas Chauncey , MD

Email: tchaunce@u.washington.edu

Dr. Chauncey is a medical oncologist who treats leukemia with bone marrow transplantation.

View Bio

Eric Chow , MD, MPH

Email: ericchow@uw.edu

Phone: (206) 667-7724

Dr. Chow studies late effects related to pediatric cancer and blood disorder therapy.

View Bio

Bruce Clurman , MD, PhD

Email: bclurman@fredhutch.org

Phone: (206) 667-4524

Dr. Clurman's studies the pathways that regulate cell growth and division in order to understand the molecular mechanisms that drive tumorigenesis and to develop new cancer therapies. His research focuses on two general areas: cellular regulation by the ubiquitin-proteasome system, and control of cell division by cyclin-dependent kinases (CDKs).His clinical practice is focused on hematopoietic stem cell transplantation.

View Bio

Laura Connelly-Smith , MBBCh, DM

Email: lauracs1@seattlecca.org

Phone: (206) 288-6938

Dr. Connelly-Smith's research is focused on the procurement of hematopoietic stem cells; therapeutic apheresis; ECP; AML; and hyperleukocytosis.

View Bio

H. Joachim Deeg , MD

Email: jdeeg@fredhutch.org

Phone: (206) 667-5985

Dr. Deeg is interested in the pathophysiology, genetics and epigenetics of MDS (role of transcription factors in regulation). He is also interested in the inflammatory responses and GVHD (effects of alpha1 anti-trypsin [AAT]), the separation of GVHD and GVL effects by AAT, and iron and allogeneic responses (in vitro, in vivo).

View Bio

David Fredricks , MD

Email: dfredric@fredhutch.org

Phone: (206) 667-1935

Dr. Fredricks's lab has identified several fastidious bacterial species that are useful markers of BV and are associated with adverse health outcomes. They are using novel cultivation methods to propagate some of these bacteria in the lab, and study how indigenous microbes interact with each other and the human host. He is currently looking for collaboration in molecular biology, microbiology, immunology, and cell biology. He is also looking for collaborators to focus on clinical epidemiology by studying microbial ecology in different human hosts.

View Bio

Jordan Gauthier , MD, MSc

Email: jgauthier@fredhutch.org

Phone: (206) 667-2713

Much of Dr. Gauthier's research has been focused on improving outcomes for patients treated with BMT or CAR T-cell therapy. Through his work, he has identified factors that can help predict the success of CAR T-cell therapy for patients who have leukemia and lymphoma.

View Bio

Ted Gooley , PhD

Email: tgooley@fredhutch.org

Phone: (206) 667-6533

Dr. Gooley's research is focused on clinical trials and methods of data analysis in stem cell transplantation.

View Bio

Ajay Gopal , MD

Email: agopal@u.washington.edu

Dr. Gopal specializes in the treatment of lymphoma, chronic lymphocytic leukemia and novel low toxicity therapies.His reseach is focused on developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity Proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.

View Bio

Philip Greenberg , MD

Email: pgreen@u.washington.edu

Phone: (206) 543-8306

Dr. Greenberg's laboratory is involved in studies elucidating the immunobiology of host T cell responses to infectious viruses and transformed cells. His group used adoptive therapy approach with cloned T cells to both, elucidate the immunobiology of human malignancies and infections and to develop novel immune-based therapies. Clinical trials of adoptive T cell therapy are now underway in patients with leukemia.

View Bio

Heather Gustafson , PhD

Email: heather.gustafson@seattlechildrens.org

Phone: (206) 884-7339

Dr. Gustafson's career has focused on harnessing existing and developing novel technology platforms that alter macrophage function through environmental manipulation. Her current research, involves engineering several macrophage phenotype targeting methods in order to understand these interactions. Her lab does this through the development of technology platforms that target specific macrophage phenotypes and alter macrophage phenotypes for therapeutic and diagnostic applications. Through the development and use of these technologies they can develop and understanding of how environmental cues impact macrophage function, how macrophage function drives disease progression and how to harness that information to engineer novel technologies to treat disease.

View Bio